Figure 1
WKYMVm upregulated FPR2 and promoted angiogenic property in HUVECs. (a) mRNA level of FPR2, normalized to glyceraldehyde 3-phosphate dehydrogenase (GAPDH), measured using reverse transcription polymerase chain reaction (RT-PCR) in human umbilical vein endothelial cells (HUVECs). Full-length RT-PCR gels are shown in Supplementary Fig. S1A. (b) Representative western blots of total-ERK and phosphorylated (p)-ERK and its densitometric data, normalized to GAPDH, in HUVECs. Full-length Western blots are shown in Supplementary Fig. S1B. (c) Tube formation assay in HUVECs. Total tube length was measured in pixels. Images were taken at a magnification of 200 × (scale bar, 100 µm). (d) Cell proliferation, evaluated by CCK-8 assay, in HUVECs. ERK inhibitor, PD98059 (20 µM final), treated with WKYMVm. The results were expressed as relative proliferation rate (%) to treated control group. (e) Cell migration assay after scratching the monolayer of HUVECs. Quantitative data is provided by calculating the gap width of scratch re-population after incubating 24 hours compared with the initial gap size at 0 hour. Images were taken at a magnification of 100× (scale bar, 100 µm). Data are given as mean ± SD. *P < 0.05 vs. control group.
